Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis: Lung

Tumor metabolic volume and total glycolytic activity and outcome in patients with lung cancer

Rathan Subramaniam, Michael Andreoli, Jessica Davison and Gregory Russo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1894;
Rathan Subramaniam
1Radiology, Boston University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Andreoli
3Boston University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Davison
3Boston University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Russo
2Radiation Oncology, Boston University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1894

Objectives To establish metabolic tumor volume and total glycolytic activity as prognostic biomarkers of outcome in patients with lung cancer.

Methods Thirty nine patients with lung cancer who had an initial staging PET/ CT at our institution between March 2007 and May 2009 were included in the study. Metabolic tumor volume and total glycolytic activity were measured by PET Edge, 38%, 50% and 60% SUVmax threshold segmentation techniques using MIMvista 3D contouring software. Unpaired t test was performed for between group analysis and Pearson correlation was performed between segmentation methods and survival time.

Results The mean age of patients (18 females and 21 males) was 67.6 (±10.6) years. The mean follow up time was 16.92 (±11.4) months. Twenty patients (51%) were dead and nineteen patients (49%) were alive. Stages of the cancers include stage 1 (n=10), stage 2 (n=6), stage 3 (n=16) and stage 4 (n=7). The mean SUVmax of patients who died was 12.7 (±3.6) and those alive was 13((±7.6) (p=0.9). The mean PET edge MTV of patients who died was 75 (95% CI 25.7-124) and those who alive was 21.9 (95% CI 5.2-38.6) (p=0.04). There were non significant results for all other segmentation methods for MTV and TGA. There was significant inverse correlation between 38% SUVmax threshold MTV and duration of survival (r = - 32%; p=0.05).

Conclusions Metabolic tumor volume segmented by PET edge and 38% SUVmax threshold method are prognostic markers of survival in lung cancer

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor metabolic volume and total glycolytic activity and outcome in patients with lung cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tumor metabolic volume and total glycolytic activity and outcome in patients with lung cancer
Rathan Subramaniam, Michael Andreoli, Jessica Davison, Gregory Russo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1894;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor metabolic volume and total glycolytic activity and outcome in patients with lung cancer
Rathan Subramaniam, Michael Andreoli, Jessica Davison, Gregory Russo
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 1894;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis: Lung

  • Impact of dual time point 18-FDG PET/CT in the assessment of pleural effusion in patients with non small cell lung cancer
  • An increase in hilar node FDG uptake after lung radiofrequency ablation in patients with lung neoplasms
  • Value of 20-s acquisition of deep-inspiration breath-hold PET/CT for diagnosis of lung nodules
Show more Oncology: Clinical Diagnosis: Lung

Lung Posters

  • Impact of dual time point 18-FDG PET/CT in the assessment of pleural effusion in patients with non small cell lung cancer
  • Benign foci in the mediastinum or hilum in non-small cell lung cancer: Description on 18F-FDG PET/CT
  • Comparison of Tc-99m-ethylenedicysteine-N-acetylglucosamine (EC-DG) and F-18 fluoro-2-deoxy-D-glucose (FDG) for diagnosing and staging patients with non small cell lung cancer
Show more Lung Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire